Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25254512 | 1.00 | MAPT (0.31) | MAPTRIPK1 | |
| SCHEMBL21813498 | 1.00 | MAPT (0.31) | MAPTRIPK1 | |
| SCHEMBL3321320 | 1.00 | MAPT (0.31) | MAPTRIPK1 | |
| SCHEMBL3275294 | 1.00 | MAPT (0.31) | MAPTRIPK1 | |
| SCHEMBL15719049 | 1.00 | MAPT (0.31) | MAPTRIPK1 | |
| SCHEMBL4775884 | 0.87 | DPP4 (0.36) | — | |
| SCHEMBL8926181 | 0.87 | DPP4 (0.36) | — | |
| SCHEMBL24016478 | 0.82 | ATM (0.35) | MAPT | |
| SCHEMBL24016463 | 0.82 | ATM (0.35) | MAPT | |
| SCHEMBL24016479 | 0.82 | ATM (0.35) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2001044499-A9 | MODIFIED LABELED COMPLEMENT COMPONENTS FOR IMMUNOASSAYS | DIAGEN CORP (US) | 2002-06-06 | — | — | WO | claimed |
| WO-2001044499-B1 | MODIFIED LABELED COMPLEMENT COMPONENTS FOR IMMUNOASSAYS | DIAGEN CORP (US) | 2002-05-10 | — | — | WO | claimed |
| WO-2001044499-A1 | MODIFIED LABELED COMPLEMENT COMPONENTS FOR IMMUNOASSAYS | DIAGEN CORPORATION (US) | 2001-06-21 | — | — | WO | claimed |
| CN-121971615-A | Application of P4HA1 inhibitor in preparation of medicines for treating congenital megacolon-associated enterocolitis | 华中科技大学同济医学院附属同济医院 | 2026-05-05 | — | — | CN | disclosed |
| US-9605001-B2 | Production of polyketides and other natural products | BUCK INSTITUTE FOR RESEARCH ON AGING (US) | 2017-03-28 | — | — | US | disclosed |
| US-20150266896-A1 | PRODUCTION OF POLYKETIDES AND OTHER NATURAL PRODUCTS | BIOTICA TECH LTD (GB) | 2015-09-24 | — | — | US | disclosed |
| EP-1521828-B1 | PRODUCTION OF POLYKETIDES | BUCK INST FOR RES ON AGING (US) | 2015-07-01 | — | — | EP | disclosed |
| US-9040259-B2 | Production of polyketides and other natural products | BUCK INSTITUTE FOR RESEARCH ON AGING (US) | 2015-05-26 | — | — | US | disclosed |
| US-20110165633-A1 | Production of Polyketides and Other Natural Products | BUCK INSTITUTE FOR RESEARCH ON AGING | 2011-07-07 | — | — | US | disclosed |
| US-20100119517-A1 | Use of Anti-MAdCAM Antibodies for the Treatment of Coeliac Disease and Tropical Sprue | PFIZER INC | 2010-05-13 | — | — | US | disclosed |
| US-7645768-B2 | Production of polyketides and other natural products | WYETH (US) | 2010-01-12 | — | — | US | disclosed |
| WO-1998001136-A1 | FORMULATIONS OF VESICANT DRUGS AND METHODS OF USE THEREOF | BAYLOR COLLEGE OF MEDICINE (US) | 1998-01-15 | — | — | WO | disclosed |
| US-5484816-A | STABILIZED VITAMIN A COMPOSITION | SHISEIDO COMPANY, LTD. (JP) | 1996-01-16 | — | — | US | disclosed |
| US-4985405-A | COMPLEX WITH AMINO ACID OR PROTEIN | BONDON, JACQUES | 1991-01-15 | — | — | US | disclosed |
| US-4824666-A | Method of large scale growth of toxoplasmic microorganisms | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 1989-04-25 | — | — | US | disclosed |
| EP-0281435-A1 | Therapeutical product based on organic silicon compounds | Gueyne, Jean (MC) | 1988-09-07 | — | — | EP | disclosed |
| US-4675176-A | EYE DISORDERS | NORDEN LABORATORIES (US) | 1987-06-23 | — | — | US | disclosed |
| EP-0033831-B1 | SUBSTITUTED NAPHTHOIC ACIDS | AMERICAN CYANAMID COMPANY (US) | 1984-04-11 | — | — | EP | disclosed |
| WO-1982003550-A1 | SUBSTITUTED NAPHTHOIC ACIDS | AMERICAN CYANAMID CO (US) | 1982-10-28 | — | — | WO | disclosed |
| EP-0033831-A2 | Substituted naphthoic acids | AMERICAN CYANAMID COMPANY (US) | 1981-08-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266896-A1 | PRODUCTION OF POLYKETIDES AND OTHER NATURAL PRODUCTS | FKBP14, FKBP4, FKBP2 | MAPT 2947/4885RIPK1 522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.